Reply to: Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights. [PDF]
J Clin OncolTran PT, Wang JH, Tang C, Kiess AP.
europepmc +1 more source
Saubermann Radium Emanation Activator
, 1900 Pamphlet advertising The Saubermann Radium Emanation Activator for the preparation of radio-active water. Intended for therapeutic use in the "sipping treatment" or "emanation therapy.
Radium Limited, U.S.A.
core
Fracture risk and survival outcomes of radium-223 therapy for bone metastases in mCRPC and the modulatory role of bone-protective therapy: a systematic review and meta-analysis. [PDF]
Front OncolXiao M, Liu F, Duan H.
europepmc +1 more source
Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer. [PDF]
Med Int (Lond), 2023 Makita K +8 more
europepmc +1 more source
Brazilian profile of Radium-223 in metastatic prostate cancer: a multicentric, retrospective study. [PDF]
EJNMMI RepSouza S +27 more
europepmc +1 more source
RADIUM-223 TREATMENT IN PATIENTS WITH PROSTATE CANCER IN ONTARIO
Background: Radium-223 is an alpha-emitting radioactive calcium-mimetic nuclide preferentially distributed into high turnover bone affected by cancer cells after intravenous administration.
Dodbiba, Lorin
core
Recurrent Extraneural Metastatic Medulloblastoma in an Adult Presenting With a Superscan and Treated With Radium-223. [PDF]
Cureus, 2023 Mou B, Cruz-Lim EM.
europepmc +1 more source
Plenary Abstracts Session & Oral Presentations
HemaSphere, Volume 10, Issue S1, June 2026.
wiley +1 more source
Prognostic factors for overall survival in patients with metastatic castration-resistant prostate cancer treated with radium-223: a meta-analysis of real-world evidence. [PDF]
Front OncolSong B, Shao H, He Y, Zhu X, Qin P.
europepmc +1 more source
Outcomes and Factors Associated with Completion of Radium-223 Therapy. [PDF]
Nucl Med Mol Imaging, 2022 Liu RF, Juwara L, Ferrario C, Probst SM.
europepmc +1 more source